Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines

Clin Infect Dis. 2022 Apr 13;74(Suppl_2):S179-S192. doi: 10.1093/cid/ciac044.

Abstract

In June 2019 the Centers for Disease Control and Prevention (CDC) convened an advisory group to assist in development of the 2021 CDC sexually transmitted infections (STI) guidelines. The advisory group on anal cancer screening and prevention met to formulate key questions in this field. The group examined published literature and abstracts to assess evidence and give recommendations for development of the CDC guidelines. This article summarizes key questions, evidence, recommendations, and areas for further research for the screening, diagnosis, and prevention of anal cancer.

Trial registration: ClinicalTrials.gov NCT02135419.

Keywords: anal cancer; anal dysplasia; high resolution anoscopy; human immunodeficiency virus (HIV); human papillomavirus (HPV).

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anus Neoplasms* / diagnosis
  • Anus Neoplasms* / prevention & control
  • Centers for Disease Control and Prevention, U.S.
  • Early Detection of Cancer
  • HIV Infections*
  • Humans
  • Papillomavirus Infections* / diagnosis
  • Papillomavirus Infections* / prevention & control
  • Sexually Transmitted Diseases* / diagnosis
  • Sexually Transmitted Diseases* / prevention & control
  • United States

Associated data

  • ClinicalTrials.gov/NCT02135419